Ultimovacs AS operates as a pharmaceutical company. The firm engages in the development of novel immunotherapies against cancer. Its product, UV1, is a therapeutic cancer vaccine that activates the immune system to recognize telomerase. The company was founded on January 26, 2011 and is headquartered in Oslo, Norway.